Hao et al. reported that they developed pentapeptide Ala-Pro-Arg-Pro-Gly (APRPG)-PEG-poly(d,l-lactide) (PDLLA) and long-circulating agent monomethoxy poly(ethylene glycol) (MPEG) as pharmaceutic adjuvant that were approved by FDA, mixed micelles containing CA-4 to target tumor neovasculature for breast cancer therapy. Here, CA4 is linked to breast cancer.